Atwater Malick LLC Sells 101 Shares of Danaher Co. (NYSE:DHR)

Atwater Malick LLC reduced its holdings in Danaher Co. (NYSE:DHR) by 6.3% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,502 shares of the conglomerate’s stock after selling 101 shares during the quarter. Atwater Malick LLC’s holdings in Danaher were worth $345,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Decker Retirement Planning Inc. bought a new position in shares of Danaher in the fourth quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America purchased a new position in Danaher in the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher in the 3rd quarter worth $40,000. FSA Wealth Management LLC purchased a new stake in shares of Danaher during the 3rd quarter valued at $50,000. Finally, Darwin Wealth Management LLC purchased a new position in Danaher in the third quarter worth $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Stephens restated an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. KeyCorp boosted their target price on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Barclays reduced their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Scotiabank initiated coverage on shares of Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective for the company. Finally, Guggenheim started coverage on shares of Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Stock Performance

Shares of DHR stock opened at $238.41 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The stock has a fifty day moving average of $234.99 and a 200 day moving average of $253.37. The firm has a market capitalization of $172.20 billion, a price-to-earnings ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. Danaher Co. has a 52 week low of $222.53 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the firm posted $2.02 EPS. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, research analysts expect that Danaher Co. will post 7.49 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is presently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.